Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas, +204

The Lancet

Hiv/aids CounsellingTreatment And PreventionWeek 48Clinical EpidemiologyClinical Trials +12

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

Josep M. Llibre, Chien‐Ching Hung, Cynthia Brinson, +11

The Lancet

Treatment And PreventionHuman RetrovirusAntiviral TherapyNon-inferiority Sword-1Virological Suppression +6

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study

Jean van Wyk, Faïza Ajana, Fiona Bisshop, +15

Clinical Infectious Diseases

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas, +18

JAIDS Journal of Acquired Immune Deficiency Syndromes

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial

Michael Aboud, Richard Kaplan, Johannes Lombaard, +14

The Lancet Infectious Diseases

First-line TherapyHuman RetrovirusImmunologyClinical TrialsAntiviral Drug Development +7

Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies

Michael Aboud, Chloe Orkin, Daniel Podzamczer, +14

The Lancet HIV

Treatment And PreventionAntiviral Drug DevelopmentAntiviral TherapyVirology100-Week Data +7

Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies

Michael Maguire, Martin Gartland, Sarah Moore, +4

AIDS

96-Week Results of Abacavir/Lamivudine versus Tenofovir/Emtricitabine, plus Efavirenz, in Antiretroviral-Naive, HIV-1-Infected Adults: Assert Study

Graeme Moyle, Hans‐Jürgen Stellbrink, Juliet Compston, +7

Antiviral Therapy

Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health

Grace A. McComsey, Sergio Lupo, David Parks, +9

AIDS

Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials

Jean van Wyk, Chloe Orkin, Rafael Rubio, +14

JAIDS Journal of Acquired Immune Deficiency Syndromes